Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.
Loria R, Laquintana V, Scalera S, Fraioli R, Caprara V, Falcone I, Bazzichetto C, Di Martile M, Rosanò L, Del Bufalo D, Bossi G, Sperduti I, Terrenato I, Visca P, Soddu S, Milella M, Ciliberto G, Falcioni R, Ferraresi V, Bon G. Loria R, et al. Among authors: laquintana v. J Exp Clin Cancer Res. 2022 Apr 19;41(1):148. doi: 10.1186/s13046-022-02354-w. J Exp Clin Cancer Res. 2022. PMID: 35440004 Free PMC article.
Prevalence and determinants of oral infection by Human Papillomavirus in HIV-infected and uninfected men who have sex with men.
Rollo F, Latini A, Pichi B, Colafigli M, Benevolo M, Sinopoli I, Sperduti I, Laquintana V, Fabbri G, Frasca M, Cristaudo A, Giuliani M, Donà MG. Rollo F, et al. Among authors: laquintana v. PLoS One. 2017 Sep 14;12(9):e0184623. doi: 10.1371/journal.pone.0184623. eCollection 2017. PLoS One. 2017. PMID: 28910359 Free PMC article.
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.
Loria R, Laquintana V, Bon G, Trisciuoglio D, Frapolli R, Covello R, Amoreo CA, Ferraresi V, Zoccali C, Novello M, Del Bufalo D, Milella M, Biagini R, D'Incalci M, Falcioni R. Loria R, et al. Among authors: laquintana v. Oncogene. 2018 Nov;37(45):5926-5938. doi: 10.1038/s41388-018-0394-x. Epub 2018 Jul 6. Oncogene. 2018. PMID: 29980789 Free PMC article.
CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions.
Bruschini S, di Martino S, Pisanu ME, Fattore L, De Vitis C, Laquintana V, Buglioni S, Tabbì E, Cerri A, Visca P, Alessandrini G, Facciolo F, Napoli C, Trombetta M, Santoro A, Crescenzi A, Ciliberto G, Mancini R. Bruschini S, et al. Among authors: laquintana v. J Cell Physiol. 2020 Mar;235(3):1877-1887. doi: 10.1002/jcp.29121. Epub 2019 Aug 9. J Cell Physiol. 2020. PMID: 31397494 Free PMC article.
Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study.
Spagnuolo M, Costantini M, Ferriero M, Varmi M, Sperduti I, Regazzo G, Cicchillitti L, Díaz Méndez AB, Cigliana G, Pompeo V, Russo A, Laquintana V, Mastroianni R, Piaggio G, Anceschi U, Brassetti A, Bove A, Tuderti G, Flammia RS, Gallucci M, Simone G, Rizzo MG. Spagnuolo M, et al. Among authors: laquintana v. J Exp Clin Cancer Res. 2020 Apr 17;39(1):68. doi: 10.1186/s13046-020-01550-w. J Exp Clin Cancer Res. 2020. PMID: 32303246 Free PMC article.
Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research Purposes.
Melis E, Gallo E, di Martino S, Gallina FT, Laquintana V, Casini B, Visca P, Ganci F, Alessandrini G, Caterino M, Cecere FL, Mandoj C, Papadantonakis A, De Bello N, Lattanzio R, Palmieri G, Garassino MC, Girard N, Conti L, Blandino G, Fazi F, Facciolo F, Pescarmona E, Ciliberto G, Marino M. Melis E, et al. Among authors: laquintana v. Front Oncol. 2020 Jul 14;10:922. doi: 10.3389/fonc.2020.00922. eCollection 2020. Front Oncol. 2020. PMID: 32760665 Free PMC article.
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchiò C, Krasniqi E, Barba M, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Barchiesi G, Mazzotta M, Marinelli D, Tomao S, Marchetti P, Valerio MR, Mirabelli R, Russo A, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Giotta F, Garufi C, Cazzaniga M, Del Medico P, Roselli M, Sanguineti G, Sperduti I, Sapino A, De Maria R, Leonetti C, Di Leo A, Ciliberto G, Falcioni R, Vici P. Bon G, et al. Among authors: laquintana v. J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3. J Exp Clin Cancer Res. 2020. PMID: 33302999 Free PMC article.
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.
Laquintana V, Mottini C, Marchesi F, Marcozzi B, Terrenato I, Sperandio E, de Latouliere L, Carrieri F, Pimpinelli F, Pontone M, Pellini R, Campo F, Conti L, Accetta C, Mandoj C, Petrone F, Di Bella O, Vujovic B, Morrone A, Compagnone M, Principato E, Pinto E, Papa E, Falcucci P, La Malfa A, Pallocca M, De Marco F, Piaggio G, Ciliberto G, Mengarelli A, di Martino S. Laquintana V, et al. Front Immunol. 2024 Jan 26;14:1221587. doi: 10.3389/fimmu.2023.1221587. eCollection 2023. Front Immunol. 2024. PMID: 38343436 Free PMC article.
122 results